In the growing peptide generics market, continued intensification and optimization of manufacturing processes are required for CDMOs to remain competitive on cost, speed, quality of peptide API while satisfying increasing regulatory requirements and sustainability goals. Learn how Bachem developed a second-generation process for the GLP-1 receptor agonist liraglutide, used for the treatment of type 2 diabetes and chronic obesity, through implementing multiple innovations in both synthesis and purification of the complex molecule.